What is the share price of Kabra Drugs Ltd (KABRADG) today?
The share price of KABRADG as on 17th July 2025 is ₹21.33. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Kabra Drugs Ltd (KABRADG) share?
The past returns of Kabra Drugs Ltd (KABRADG) share are- Past 1 week: -3.24%
- Past 1 month: 66.42%
- Past 3 months: 92.51%
- Past 6 months: 112.03%
- Past 1 year: 156.99%
- Past 3 years: 435.93%
- Past 5 years: 467.29%
What are the peers or stocks similar to Kabra Drugs Ltd (KABRADG)?
The peers or stocks similar to Kabra Drugs Ltd (KABRADG) include:What is the market cap of Kabra Drugs Ltd (KABRADG) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kabra Drugs Ltd (KABRADG) is ₹48.17 Cr as of 17th July 2025.What is the 52 week high and low of Kabra Drugs Ltd (KABRADG) share?
The 52-week high of Kabra Drugs Ltd (KABRADG) is ₹22.77 and the 52-week low is ₹8.30.What is the PE and PB ratio of Kabra Drugs Ltd (KABRADG) stock?
The P/E (price-to-earnings) ratio of Kabra Drugs Ltd (KABRADG) is -44.20. The P/B (price-to-book) ratio is 44.61.Which sector does Kabra Drugs Ltd (KABRADG) belong to?
Kabra Drugs Ltd (KABRADG) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Kabra Drugs Ltd (KABRADG) shares?
You can directly buy Kabra Drugs Ltd (KABRADG) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Kabra Drugs Ltd
KABRADG Share Price
21.334.97% (+1.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
KABRADG Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
KABRADG Performance & Key Metrics
KABRADG Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -44.20 | 44.61 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.40 | 6.48 | 0.81% |
KABRADG Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
KABRADG Company Profile
Kabra Drugs Limited is engaged in manufacturing of ether derivatives and pharmaceutical formulations. The Company operates through manufacturing of drugs segment.
SUNPHARMA
PE Ratio
37.34
37.34
1Y Return
6.85%
6.85%
Buy Reco %
84.85
84.85
CIPLA
PE Ratio
22.61
22.61
1Y Return
1.61%
1.61%
Buy Reco %
68.75
68.75
TORNTPHARM
PE Ratio
61.26
61.26
1Y Return
14.59%
14.59%
Buy Reco %
70.83
70.83
MANKIND
PE Ratio
54.42
54.42
1Y Return
23.40%
23.40%
Buy Reco %
81.25
81.25
DRREDDY
PE Ratio
18.53
18.53
1Y Return
5.28%
5.28%
Buy Reco %
48.39
48.39
KABRADG Forecast
KABRADG Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
KABRADG
KABRADG
Income
Balance Sheet
Cash Flow
Annual Normal View
KABRADG Income Statement
KABRADG Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 7.72 | 1.82 | 0.01 | 0.02 | 0.00 | 0.00 | 0.01 | 0.00 | 0.64 | 0.64 | ||||||||||
Raw Materials | 4.81 | 1.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.72 | 1.72 | ||||||||||
| Power & Fuel Cost | 0.18 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Employee Cost | 0.83 | 1.18 | 0.03 | 0.00 | 0.05 | 0.09 | 0.23 | 0.40 | ||||||||||||
| Selling & Administrative Expenses | 0.31 | 0.10 | 0.10 | 0.05 | 0.10 | 0.08 | 0.09 | 0.30 | ||||||||||||
| Operating & Other expenses | 1.04 | 1.14 | 0.01 | 0.00 | -0.00 | 0.01 | 0.02 | 0.04 | ||||||||||||
EBITDA | 0.55 | -1.96 | -0.13 | -0.03 | -0.15 | -0.18 | -0.33 | -0.74 | -1.08 | -1.08 | ||||||||||
| Depreciation/Amortization | 0.24 | 0.14 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | ||||||||||
| PBIT | 0.31 | -2.10 | -0.16 | -0.06 | -0.18 | -0.19 | -0.33 | -0.74 | -1.09 | -1.09 | ||||||||||
| Interest & Other Items | 0.17 | 0.25 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 0.14 | -2.35 | -0.17 | -0.06 | -0.18 | -0.19 | -0.33 | -0.74 | -1.09 | -1.09 | ||||||||||
| Taxes & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | 0.13 | -2.35 | -0.17 | -0.06 | -0.18 | -0.19 | -0.33 | -0.74 | -1.09 | -1.09 | ||||||||||
| EPS | 0.30 | -5.35 | -0.39 | -0.14 | -0.41 | -0.43 | -0.75 | -1.69 | -0.99 | -2.48 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
KABRADG Company Updates
KABRADG Stock Peers
KABRADG Past Performance & Peer Comparison
KABRADG Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kabra Drugs Ltd | -44.20 | 44.61 | — |
| Sun Pharmaceutical Industries Ltd | 37.34 | 5.63 | 0.94% |
| Cipla Ltd | 22.61 | 3.81 | 1.08% |
| Torrent Pharmaceuticals Ltd | 61.26 | 15.42 | 0.92% |
KABRADG Stock Price Comparison
Compare KABRADG with any stock or ETFCompare KABRADG with any stock or ETF
KABRADG
KABRADG Holdings
KABRADG Shareholdings
KABRADG Promoter Holdings Trend
KABRADG Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
KABRADG Institutional Holdings Trend
KABRADG Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 14.91%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
KABRADG Shareholding Pattern
KABRADG Shareholding Pattern
KABRADG Shareholding History
KABRADG Shareholding History
Foreign Institutions
smallcases containing KABRADG stock
smallcases containing KABRADG stock
Looks like this stock is not in any smallcase yet.
KABRADG Events
KABRADG Events
KABRADG Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KABRADG has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
KABRADG Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
KABRADG has not given any dividends in last 5 years
KABRADG Dividends
KABRADG Dividends
Hmm, looks like data is unavailable here. Please come back after some timeKABRADG Stock News & Opinions
KABRADG Stock News & Opinions
Articles & Videos
Corporate
Kabra Drugs to convene board meeting
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 18 June 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Kabra Drugs reports standalone net profit of Rs 0.39 crore in the March 2025 quarter
Net profit of Kabra Drugs reported to Rs 0.39 crore in the quarter ended March 2025 as against net loss of Rs 0.37 crore during the previous quarter ended March 2024. There were no Sales reported in the quarter ended March 2025 and during the previous quarter ended March 2024. For the full year,net loss reported to Rs 1.09 crore in the year ended March 2025 as against net loss of Rs 0.74 crore during the previous year ended March 2024. There were no Sales reported in the year ended March 2025 and during the previous year ended March 2024.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Kabra Drugs schedules board meeting
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Kabra Drugs reports standalone net loss of Rs 0.54 crore in the December 2024 quarter
Net Loss of Kabra Drugs reported to Rs 0.54 crore in the quarter ended December 2024 as against net loss of Rs 0.11 crore during the previous quarter ended December 2023. There were no Sales reported in the quarter ended December 2024 and during the previous quarter ended December 2023.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Kabra Drugs to conduct board meeting
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Kabra Drugs to conduct EGM
Kabra Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 2 January 2025 .Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Kabra Drugs schedules board meeting
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 4 December 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Kabra Drugs reports standalone net loss of Rs 0.40 crore in the September 2024 quarter
Net Loss of Kabra Drugs reported to Rs 0.40 crore in the quarter ended September 2024 as against net loss of Rs 0.13 crore during the previous quarter ended September 2023. There were no Sales reported in the quarter ended September 2024 and during the previous quarter ended September 2023.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Kabra Drugs to convene board meeting
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Kabra Drugs to consider Fund Raising
Kabra Drugs will hold a meeting of the Board of Directors of the Company on 4 November 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 100%, vs industry avg of 10.15%
Over the last 5 years, market share stayed at 0%